<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/aura-biosciences-inc-logo-1200x675.png/query-dj0yMDIxMTEyMzA3NTMxNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/aura-biosciences-inc-logo-1200x675.png/query-dj0yMDIxMTEyMzA3NTMxNw"/>Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the firm's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $5.64, for a total value of $39,044,986.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.</p><h2>Aura Biosciences Price Performance</h2><ul><li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li></ul><p>AURA opened at $8.19 on Tuesday. The stock's 50 day simple moving average is $6.76 and its 200 day simple moving average is $6.08. Aura Biosciences, Inc. has a 1 year low of $4.34 and a 1 year high of $9.53. The firm has a market cap of $525.80 million, a price-to-earnings ratio of -4.58 and a beta of 0.37. </p><p>Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.10).  As a group, sell-side analysts anticipate that  Aura Biosciences, Inc. will post -1.63 EPS for the current year. </p><h2>Analyst Ratings Changes</h2><hr/><hr/><p>A number of brokerages recently issued reports on AURA. HC Wainwright boosted their price target on Aura Biosciences from $22.00 to $24.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, April 29th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Aura Biosciences in a report on Friday, March 27th. Finally, Wall Street Zen upgraded Aura Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 4th. Three investment analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat.com, Aura Biosciences  has a consensus rating of &#34;Hold&#34; and an average target price of $21.50.</p><p><b>Read Our Latest Stock Analysis on AURA</b></p><h2>Institutional Trading of Aura Biosciences</h2><p>Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in shares of  Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock worth $38,000 after purchasing an additional 3,206 shares in the last quarter.  Tower Research Capital LLC TRC grew its position in  Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after purchasing an additional 2,104 shares during the last quarter.  ProShare Advisors LLC purchased a new stake in  Aura Biosciences during the 4th quarter valued at about $59,000.  Water Island Capital LLC purchased a new stake in  Aura Biosciences during the 3rd quarter valued at about $64,000.  Finally, 49 Wealth Management LLC purchased a new stake in  Aura Biosciences during the 3rd quarter valued at about $66,000. 96.75% of the stock is owned by institutional investors. </p><h2>About Aura Biosciences</h2><p> (Get Free Report)</p><p>Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.  </p><p>The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.</p><h2>Read More</h2><ul><li>Five stocks we like better than Aura Biosciences</li><li>Before the Moon Base Gets Built, These 4 Companies Win</li><li>Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases</li><li>3 Stocks That Win If Inflation Surprises to the Downside</li><li>MercadoLibre Boldly Invests in Growth: Discount Deepens</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Aura Biosciences?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Aura Biosciences and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260413094022_pushgold-bullion-163553640.jpg"/></p><div><p>Trump's gold order: the announcement they won't put on the front page</p><p>On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...</p><p><span>Reagan Gold Group</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA5MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="593" original-src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png"/></p><div><p>Iran's New Leader Just Said Something That Should Terrify Every American</p><p>Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...</p><p><span>American Alternative</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20260211141634_blobid0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1100" height="618" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20260211141634_blobid0.png"/></p><div><p>Read this or regret it forever</p><p>Three Nobel Prize Winners expose this once-in-a-generation wealth shift:  “Don’t Say I Didn’t Warn You”  P...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTI3NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTI3NA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260430135620_pushspace-x-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260430135620_pushspace-x-3.jpg"/></p><div><p>Before you buy SpaceX shares, consider this alternative approach</p><p>SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...</p><p><span>Weiss Ratings</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIyNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311160021_pushainewer-1.jpg"/></p><div><p>CODE RED: AI Meltdown Imminent?</p><p>After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...</p><p><span>Paradigm Press</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE4OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420142948_pushiphone-410311640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420142948_pushiphone-410311640.jpg"/></p><div><p>Your book attached</p><p>Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE3Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTE3Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>I was right about SpaceX</p><p>Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311143358_pushainewer-8.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260311143358_pushainewer-8.jpg"/></p><div><p>&#34;Computers are about to become obsolete&#34; - George Gilder. Here’s why.</p><p>George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...</p><p><span>Eagle Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIzNw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTIzNw"/></p></div></div></div>                     </div>                 </div></div>

AURA

<p>Matrix Capital Management Comp sold 6,922,870 shares of Aura Biosciences (NASDAQ:AURA) at an average price of $5.64, totaling approximately $39 million. This transaction was disclosed in a filing with the SEC. Aura Biosciences has a market cap of $525.80 million and reported a quarterly EPS of ($0.50), missing estimates. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $21.50. The company focuses on developing novel therapies for cancer treatment.</p>

Matrix Capital Management Comp Sells 6,922,870 Shares of Aura Biosciences (NASDAQ:AURA) Stock